Supernus Pharmaceuticals Earnings Estimate
| SUPN Stock | USD 37.74 0.13 0.34% |
Supernus Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Supernus Pharmaceuticals' earnings estimates, investors can diagnose different trends across Supernus Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Supernus Pharmaceuticals' Gross Profit is very stable compared to the past year. As of the 18th of January 2025, Pretax Profit Margin is likely to grow to 0, while Operating Profit Margin is likely to drop (0.01).
Supernus |
Supernus Pharmaceuticals Earnings Estimation Breakdown
The calculation of Supernus Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Supernus Pharmaceuticals is estimated to be 0.714175 with the future projection ranging from a low of 0.7075 to a high of 0.725. Please be aware that this consensus of annual earnings estimates for Supernus Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.71 Lowest | Expected EPS | 0.72 Highest |
Supernus Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Supernus Pharmaceuticals' value are higher than the current market price of the Supernus Pharmaceuticals stock. In this case, investors may conclude that Supernus Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Supernus Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 5 | 49.22% | 0.69 | 0.714175 | 1.06 |
Supernus Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Supernus Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Supernus Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Supernus Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Supernus Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Supernus Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Supernus Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Supernus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | 0.44 | 0.69 | 0.25 | 56 | ||
2024-08-06 | 2024-06-30 | 0.31 | 0.36 | 0.05 | 16 | ||
2024-05-08 | 2024-03-31 | 0.38 | 0.26 | -0.12 | 31 | ||
2024-02-27 | 2023-12-31 | 0.55 | 0.89 | 0.34 | 61 | ||
2023-11-08 | 2023-09-30 | 0.08 | 0.24 | 0.16 | 200 | ||
2023-08-08 | 2023-06-30 | -0.23 | -0.02 | 0.21 | 91 | ||
2023-05-09 | 2023-03-31 | 0.17 | 0.29 | 0.12 | 70 | ||
2023-02-28 | 2022-12-31 | 0.68 | 0.43 | -0.25 | 36 | ||
2022-11-08 | 2022-09-30 | 0.36 | 0.03 | -0.33 | 91 | ||
2022-08-04 | 2022-06-30 | 0.29 | 0.14 | -0.15 | 51 | ||
2022-05-09 | 2022-03-31 | 0.24 | 0.43 | 0.19 | 79 | ||
2022-02-28 | 2021-12-31 | 0.24 | 0.04 | -0.2 | 83 | ||
2021-11-03 | 2021-09-30 | 0.23 | 0.4 | 0.17 | 73 | ||
2021-08-04 | 2021-06-30 | 0.2 | 0.43 | 0.23 | 115 | ||
2021-05-05 | 2021-03-31 | 0.24 | 0.11 | -0.13 | 54 | ||
2021-02-25 | 2020-12-31 | 0.52 | 0.57 | 0.05 | 9 | ||
2020-11-03 | 2020-09-30 | 0.3 | 0.74 | 0.44 | 146 | ||
2020-08-17 | 2020-06-30 | 0.42 | 0.65 | 0.23 | 54 | ||
2020-05-05 | 2020-03-31 | 0.28 | 0.4 | 0.12 | 42 | ||
2020-02-25 | 2019-12-31 | 0.6 | 0.62 | 0.02 | 3 | ||
2019-11-05 | 2019-09-30 | 0.6 | 0.54 | -0.06 | 10 | ||
2019-08-06 | 2019-06-30 | 0.58 | 0.61 | 0.03 | 5 | ||
2019-05-07 | 2019-03-31 | 0.47 | 0.34 | -0.13 | 27 | ||
2019-02-26 | 2018-12-31 | 0.27 | 0.48 | 0.21 | 77 | ||
2018-11-06 | 2018-09-30 | 0.41 | 0.52 | 0.11 | 26 | ||
2018-08-07 | 2018-06-30 | 0.43 | 0.57 | 0.14 | 32 | ||
2018-05-08 | 2018-03-31 | 0.33 | 0.49 | 0.16 | 48 | ||
2018-02-27 | 2017-12-31 | 0.27 | 0.44 | 0.17 | 62 | ||
2017-11-06 | 2017-09-30 | 0.27 | 0.29 | 0.02 | 7 | ||
2017-08-02 | 2017-06-30 | 0.24 | 0.32 | 0.08 | 33 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2017-01-20 | 2016-12-31 | 0.34 | 0.37 | 0.03 | 8 | ||
2016-12-13 | 2016-09-30 | 0.34 | 0.37 | 0.03 | 8 | ||
2016-08-02 | 2016-06-30 | 0.13 | 0.18 | 0.05 | 38 | ||
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2016-03-02 | 2015-12-31 | 0.06 | 0.14 | 0.08 | 133 | ||
2015-11-03 | 2015-09-30 | 0.02 | 0.08 | 0.06 | 300 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2015-05-05 | 2015-03-31 | -0.01 | 0.02 | 0.03 | 300 | ||
2015-03-10 | 2014-12-31 | -0.12 | 0.1 | 0.22 | 183 | ||
2014-11-11 | 2014-09-30 | 0.36 | 0.39 | 0.03 | 8 | ||
2014-08-11 | 2014-06-30 | -0.15 | 0.08 | 0.23 | 153 | ||
2014-05-12 | 2014-03-31 | -0.41 | -0.35 | 0.06 | 14 | ||
2014-03-12 | 2013-12-31 | -0.55 | -0.39 | 0.16 | 29 | ||
2013-11-12 | 2013-09-30 | -0.67 | -0.64 | 0.03 | 4 | ||
2013-08-13 | 2013-06-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2013-05-13 | 2013-03-31 | -0.71 | -0.6 | 0.11 | 15 | ||
2013-03-14 | 2012-12-31 | -0.71 | -0.51 | 0.2 | 28 | ||
2012-11-07 | 2012-09-30 | -0.62 | -0.55 | 0.07 | 11 | ||
2012-08-10 | 2012-06-30 | -0.48 | -0.61 | -0.13 | 27 |
About Supernus Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Supernus Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Supernus Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Supernus Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | 554.9 M | 582.7 M | |
| Retained Earnings Total Equity | 553.4 M | 581.1 M | |
| Price Earnings Ratio | 1.1 K | 1.1 K | |
| Price Earnings To Growth Ratio | (14.09) | (13.39) |
Pair Trading with Supernus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Supernus Stock
| 0.73 | VINC | Vincerx Pharma | PairCorr |
| 0.68 | DRRX | Durect | PairCorr |
| 0.68 | VKTX | Viking Therapeutics | PairCorr |
| 0.67 | VALN | Valneva SE ADR | PairCorr |
| 0.63 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.06 | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.